NASDAQ:ICPT - Intercept Pharmaceuticals Stock Price, News & Analysis

$60.90
-2.08 (-3.30 %)
(As of 08/25/2019 04:00 PM ET)
Today's Range
$60.45
Now: $60.90
$64.5150
50-Day Range
$59.20
MA: $67.44
$80.46
52-Week Range
$58.21
Now: $60.90
$133.74
Volume488,948 shs
Average Volume554,765 shs
Market Capitalization$1.99 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.32
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ICPT
CUSIP45845P10
Phone646-747-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$179.80 million
Book Value$5.36 per share

Profitability

Net Income$-309,240,000.00
Net Margins-143.57%

Miscellaneous

Employees483
Market Cap$1.99 billion
Next Earnings Date10/30/2019 (Estimated)
OptionableOptionable

Receive ICPT News and Ratings via Email

Sign-up to receive the latest news and ratings for ICPT and its competitors with MarketBeat's FREE daily newsletter.


Intercept Pharmaceuticals (NASDAQ:ICPT) Frequently Asked Questions

What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) issued its earnings results on Wednesday, August, 7th. The biopharmaceutical company reported ($2.28) earnings per share for the quarter, beating analysts' consensus estimates of ($2.51) by $0.23. The biopharmaceutical company had revenue of $66.30 million for the quarter, compared to analyst estimates of $58.78 million. Intercept Pharmaceuticals had a negative net margin of 143.57% and a negative return on equity of 534.42%. The company's quarterly revenue was up 52.2% on a year-over-year basis. During the same quarter last year, the business posted ($2.58) earnings per share. View Intercept Pharmaceuticals' Earnings History.

When is Intercept Pharmaceuticals' next earnings date?

Intercept Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, October 30th 2019. View Earnings Estimates for Intercept Pharmaceuticals.

What guidance has Intercept Pharmaceuticals issued on next quarter's earnings?

Intercept Pharmaceuticals issued an update on its FY 2019 earnings guidance on Wednesday, August, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $235-245 million, compared to the consensus revenue estimate of $242.29 million.

What price target have analysts set for ICPT?

21 brokers have issued 12 month price objectives for Intercept Pharmaceuticals' stock. Their predictions range from $68.00 to $243.00. On average, they expect Intercept Pharmaceuticals' stock price to reach $142.1510 in the next twelve months. This suggests a possible upside of 133.4% from the stock's current price. View Analyst Price Targets for Intercept Pharmaceuticals.

What is the consensus analysts' recommendation for Intercept Pharmaceuticals?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last year. There are currently 2 sell ratings, 4 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intercept Pharmaceuticals.

What are Wall Street analysts saying about Intercept Pharmaceuticals stock?

Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:
  • 1. Stifel Nicolaus analysts commented, "We are reiterating our Hold rating on ICPT after the company reported a slight 2Q19 beat on Ocaliva revenues, which appear to have been aided by a benefit in channel inventories. With that said, our thesis remains unchanged and we think there are too many unknown variables in terms of OCA’s potential adcom/approval and launch in NASH for us to be comfortable recommending the stock here. Management remains on track to file its NDA for OCA in NASH by the end of this quarter followed by its MAA filing in the EU in 4Q19. We think investor focus remains on the potential for OCA in NASH and in particular: whether or not ICPT’s filing of a NDA for OCA in NASH (rather than a sNDA) can lead to bi- furcated/indication based pricing, potential payer/reimbursement dynamics in the NASH category and the use of non-invasive biomarkers vs. biopsy for diagnosis." (8/12/2019)
  • 2. According to Zacks Investment Research, "Intercept’s lead drug Ocaliva’s performance has been strong in the year so far. Management’s efforts to increase awareness about the label update of Ocaliva in 2018 and expand sales force across the United States, thereafter, are reaping results. Solid growth in new patient enrollment is likely to drive sales in 2019. Meanwhile, Intercept is working to expand the drug’s label in the promising NASH space. While the failure of Gilead Sciences’ late-stage study on selonsertib, involving patients afflicted with compensated cirrhosis (F4) due to NASH puts Intercept ahead in the race, the additional results from the REGENERATE study for NASH were mixed and did not impress investors. However, the company’s dependence on a single product for growth is a concern. Shares have underperformed the industry in the year so far." (7/15/2019)
  • 3. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $170 PT. Positive Ph3 data on fibrosis de-risk this binary readout. Intercept announced this morning that the 25mg dose hit on one of the key endpoints, which is a one point change in fibrosis stage (OCA 23.1%, placebo 11.9%, p-value=0.0002). They saw a numerical trend on NASH resolution in the 25mg. Although this endpoint did not hit (25mg p-value=0.1268), we believe that the data profile for OCA will support approval; fibrosis is relevant for potential liver outcomes. Since there was a p-value of 0.0013 when F1 co-morbidities were added, we are interested to see more analysis around NASH resolution." (2/19/2019)

Has Intercept Pharmaceuticals been receiving favorable news coverage?

Media stories about ICPT stock have trended positive recently, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Intercept Pharmaceuticals earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the stock's share price in the near term. View News Stories for Intercept Pharmaceuticals.

Are investors shorting Intercept Pharmaceuticals?

Intercept Pharmaceuticals saw a decrease in short interest in the month of July. As of July 31st, there was short interest totalling 5,103,200 shares, a decrease of 12.3% from the June 30th total of 5,815,900 shares. Based on an average daily trading volume, of 681,800 shares, the days-to-cover ratio is presently 7.5 days. Currently, 22.9% of the company's shares are sold short. View Intercept Pharmaceuticals' Current Options Chain.

Who are some of Intercept Pharmaceuticals' key competitors?

What other stocks do shareholders of Intercept Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), Netflix (NFLX), Alibaba Group (BABA), Ionis Pharmaceuticals (IONS), NVIDIA (NVDA), Celgene (CELG), Biogen (BIIB) and Regeneron Pharmaceuticals (REGN).

Who are Intercept Pharmaceuticals' key executives?

Intercept Pharmaceuticals' management team includes the folowing people:
  • Dr. Mark Pruzanski, Founder, CEO, Pres & Director (Age 51)
  • Mr. Sandip S. Kapadia, CFO, Treasurer & Principal Accounting Officer (Age 49)
  • Mr. Jerome B. Durso, Chief Operating Officer (Age 51)
  • Mr. Ryan T. Sullivan, Gen. Counsel & Sec. (Age 43)
  • Dr. Gail Cawkwell, Sr. VP of Medical Affairs, Safety & Pharmacovigilance (Age 57)

Who are Intercept Pharmaceuticals' major shareholders?

Intercept Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.85%), First Trust Advisors LP (3.67%), Samsara BioCapital LLC (1.11%), Northern Trust Corp (0.99%), EULAV Asset Management (0.66%) and Price T Rowe Associates Inc. MD (0.60%). Company insiders that own Intercept Pharmaceuticals stock include Christian Weyer, David Shapiro, Francesco Micheli, Keith Michael Gottesdiener, Lisa Bright, Luca Benatti, Mark Pruzanski, Paolo Fundaro, Rachel Mcminn, Richard J Kim, Sandip Kapadia, SPA Genextra and Srinivas Akkaraju. View Institutional Ownership Trends for Intercept Pharmaceuticals.

Which institutional investors are selling Intercept Pharmaceuticals stock?

ICPT stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Pictet Asset Management Ltd., Parametric Portfolio Associates LLC, LPL Financial LLC, Pinnacle Associates Ltd., South Dakota Investment Council, Trexquant Investment LP and Man Group plc. Company insiders that have sold Intercept Pharmaceuticals company stock in the last year include Christian Weyer, David Shapiro, Lisa Bright, Mark Pruzanski, Paolo Fundaro, SPA Genextra and Srinivas Akkaraju. View Insider Buying and Selling for Intercept Pharmaceuticals.

Which institutional investors are buying Intercept Pharmaceuticals stock?

ICPT stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., First Trust Advisors LP, Samsara BioCapital LLC, Nuveen Asset Management LLC, Perceptive Advisors LLC, UBS Asset Management Americas Inc., Scopia Capital Management LP and Rock Springs Capital Management LP. Company insiders that have bought Intercept Pharmaceuticals stock in the last two years include Francesco Micheli, Keith Michael Gottesdiener, Luca Benatti, Mark Pruzanski and Srinivas Akkaraju. View Insider Buying and Selling for Intercept Pharmaceuticals.

How do I buy shares of Intercept Pharmaceuticals?

Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intercept Pharmaceuticals' stock price today?

One share of ICPT stock can currently be purchased for approximately $60.90.

How big of a company is Intercept Pharmaceuticals?

Intercept Pharmaceuticals has a market capitalization of $1.99 billion and generates $179.80 million in revenue each year. The biopharmaceutical company earns $-309,240,000.00 in net income (profit) each year or ($10.86) on an earnings per share basis. Intercept Pharmaceuticals employs 483 workers across the globe.View Additional Information About Intercept Pharmaceuticals.

What is Intercept Pharmaceuticals' official website?

The official website for Intercept Pharmaceuticals is http://www.interceptpharma.com/.

How can I contact Intercept Pharmaceuticals?

Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at 646-747-1000 or via email at [email protected]


MarketBeat Community Rating for Intercept Pharmaceuticals (NASDAQ ICPT)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  934 (Vote Outperform)
Underperform Votes:  551 (Vote Underperform)
Total Votes:  1,485
MarketBeat's community ratings are surveys of what our community members think about Intercept Pharmaceuticals and other stocks. Vote "Outperform" if you believe ICPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel